Loading...
•
Mar 31, 2024
Phibro Q3 2024 Earnings Report
Phibro Animal Health Corporation reported an increase in net sales and adjusted EBITDA, but a decrease in net income and diluted earnings per share.
Key Takeaways
Phibro Animal Health Corporation announced its third quarter results, showing a 7% increase in net sales to $263.2 million and a 9% increase in Adjusted EBITDA to $29.7 million. However, net income decreased by $1.6 million to $8.4 million, and diluted earnings per share decreased by $0.04 to $0.21. The company has updated its financial guidance for the year ending June 30, 2024, projecting net income between $7 million and $12 million, and diluted EPS between $0.17 and $0.30.
Net sales increased by 7% to $263.2 million.
Net income decreased by $1.6 million to $8.4 million.
Adjusted EBITDA increased by 9% to $29.7 million.
Adjusted diluted EPS increased by 9% to $0.31.
Revenue by Segment
Forward Guidance
Phibro has updated its fiscal year 2024 guidance, reflecting recent developments including acquisition-related expenses and insurance proceeds. The guidance is on a standalone basis without giving effect to the acquisition of Zoetis’ Medicated Feed Additive portfolio.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...